Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Kezar Life Sciences Price Performance
Shares of KZR Stock opened at $10.04 on Thursday. Kezar Life Sciences has a 12-month low of $4.30 and a 12-month high of $18.55. The business has a 50 day simple moving average of $8.15 and a 200 day simple moving average of $11.02. The company has a debt-to-equity ratio of 0.04, a current ratio of 35.25 and a quick ratio of 35.25.
Kezar Life Sciences (NASDAQ:KZR - Get Rating) last issued its quarterly earnings data on Thursday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.03. Sell-side analysts anticipate that Kezar Life Sciences will post -1.13 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on KZR shares. Jonestrading increased their price objective on Kezar Life Sciences from $17.00 to $20.00 in a report on Tuesday, June 28th. Wells Fargo & Company increased their price objective on Kezar Life Sciences from $13.00 to $17.00 and gave the stock an "overweight" rating in a report on Tuesday, June 28th.